TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02829060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin 100 MG, 7d
Description: 7 day course, 100 mg twice daily, PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin 100 MG, 7d
Description: 7 day course, 100 mg twice daily, PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin, 5mg/kg
Description: Peri-operative dose: 5 mg/kg of ideal body weight, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin, 5mg/kg
Description: Peri-operative dose: 5 mg/kg of ideal body weight, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin, 5mg/kg
Description: Peri-operative dose: 5 mg/kg of ideal body weight, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin, 5mg/kg
Description: Peri-operative dose: 5 mg/kg of ideal body weight, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin, 5mg/kg
Description: Peri-operative dose: 5 mg/kg of ideal body weight, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin, 5mg/kg
Description: Peri-operative dose: 5 mg/kg of ideal body weight, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin 2g
Description: Peri-operative dose: 2 grams, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin 2g
Description: Peri-operative dose: 2 grams, IV
Study: NCT03659825

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Ester
Description: Flavored sports drink containing deltaG (betahydroxybutyrate monoester) as the sole active ingredient, diluted with water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Ester
Description: Flavored sports drink containing deltaG (betahydroxybutyrate monoester) as the sole active ingredient, diluted with water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Taste Matched Placebo
Description: Placebo that tastes similar to active intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Taste Matched Placebo
Description: Placebo that tastes similar to active intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic exposure
Description: Participants will breath through a mask to provide the amount of oxygen typically seen at 16-17,000ft of altitude.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypoxic exposure
Description: Participants will breath through a mask to provide the amount of oxygen typically seen at 16-17,000ft of altitude.
Study: NCT01356368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, Gemzar, Docetaxel, Alimta
Description: Patients will be assigned to treatment according to the molecular biological results which will analyze excision repair cross-complementing (ERCC1), ribonucleotide reductase subunit M1 (RRM1) and beta-tubulin genes in primary tumor cells which are present in tissues and peripheral blood.
Study: NCT01613651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo RALP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo RALP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intraoperative complication management/prevention
Description: Undergo placement of pelvic drain
Study: NCT03238547

Intervention type: DIAGNOSTIC_TEST
Intervention: semi-quantitative urine albumin-to-creatinine ratio test
Description: measurement of urine albumin-to-creatinine ratio using URiSCAN 2ACR, a semi-quantitative urine albumin-to-creatinine ratio test

Intervention type: DIAGNOSTIC_TEST
Intervention: standard quantitative spot urine albumin-to-creatinine ratio
Description: measurement of urine albumin-to-creatinine ratio using a standard turbidimetric immunoassay
Study: NCT01931410

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Study: NCT02829060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin 2g
Description: Peri-operative dose: 2 grams, IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin 2g
Description: Peri-operative dose: 2 grams, IV
Study: NCT01749787

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via infusion once per week for 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100 at 420 mcg
Study: NCT01935258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosomatic therapy
Description: Psychosomatic therapy delivered by a psychosomatic therapist, consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care as usual
Description: usual care of the general practitioner

Intervention type: OTHER
Group type: OTHER
Intervention: care as usual
Description: usual care of the general practitioner
Study: NCT03162887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive a research team member-led breast cancer and mammogram educational module

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo a web-based decision counseling session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive a next steps document
Study: NCT01861678

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High tie of IMA
Description: Conventional technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low tie of IMA
Description: Technique for preserving left colic arterial perfusion
Study: NCT04157712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALZ-801 or matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALZ-801 or matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALZ-801 or matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALZ-801 or matching placebo
Study: NCT00218556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment for depression
Description: Cognitive behavioral intervention to prevent depressive symptoms during treatment for hepatitis C
Study: NCT02227745

Intervention type: DRUG
Intervention: Dorzolamide hydrochloride (2%)
Description: Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed

Intervention type: DRUG
Intervention: Placebo Sodium hyaluronate 4mg
Description: Intervention: Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed.
Study: NCT01369589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-552
Description: P-552 will be administered as 10 mL mouth rinse to be swished in the mouth fro 30 seconds and then completely expectorated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-552
Description: P-552 will be administered as 10 mL mouth rinse to be swished in the mouth fro 30 seconds and then completely expectorated.
Study: NCT03519880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Mask Interface
Description: Subjects enrolled in the study will received a custom designed, 3D printed, non-invasive ventilation mask interface.
Study: NCT03631511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: direct pulp capping with RetroMTA
Description: The study included seven caries-free third molars from three adults. These teeth were subjected to pulp exposure, direct capping with RetroMTA, and restoration with a composite resin. Seven months later, the teeth were clinically and radiographically evaluated. The teeth were then extracted and subjected to histological processing and evaluation.
Study: NCT02458014

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02829060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin 100 mg, 48 hrs
Description: 48 hour course, 100 mg twice daily, PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin 100 mg, 48 hrs
Description: 48 hour course, 100 mg twice daily, PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin, 80 mg, 7d
Description: 7 day course, 80 mg daily, IM or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin, 80 mg, 48hr
Description: 48 hour course, 80 mg daily, IM or IV
Study: NCT02095418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil, Corticosteroids
Description: tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1500mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids, Mycophenolate mofetil
Description: tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1000mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (3 month±2weeks)
Study: NCT02006888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-10090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-10090

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03485391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: Practice guidelines have identified that trauma-focused psychotherapies have most evidence for treatment PTSD. Prolonged Exposure (PE) is one type of trauma-focused psychotherapy. PE teaches you to gradually approach trauma-related memories, feelings, and situations that you have been avoiding since your trauma. By confronting these challenges, you can decrease your PTSD symptoms. Treatment will last anywhere from 8-12 weeks for 75-90 minutes, once per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure
Description: Practice guidelines have identified that trauma-focused psychotherapies have most evidence for treatment PTSD. Prolonged Exposure (PE) is one type of trauma-focused psychotherapy. PE teaches you to gradually approach trauma-related memories, feelings, and situations that you have been avoiding since your trauma. By confronting these challenges, you can decrease your PTSD symptoms. Treatment will last anywhere from 8-12 weeks for 75-90 minutes, once per week.
Study: NCT01727401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Description: Fondaparinux once daily sc injections at a dose of 2.5 mg if renal clearance of creatinine above 50 ml/min or Fondaparinux once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
Study: NCT00261274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A-ECO

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT00371826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine (Calcineurin Inhibitor (CNI))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (Calcineurin Inhibitor (CNI))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (Calcineurin Inhibitor (CNI))

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisone/prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisone/prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisone/prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate sodium (MPA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium (MPA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium (MPA)
Study: NCT00481143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICL670/Deferasirox
Study: NCT00219739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg
Study: NCT01369589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as 10 mL mouth rinse to be swished in the mouth for 30 seconds and then completely expectorated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as 10 mL mouth rinse to be swished in the mouth for 30 seconds and then completely expectorated.
Study: NCT02404454

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic metroplasty

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autocross-linked acid hyaluronic gel
Description: Patients received adhesion barrier with 5 ml of autocross-linked acid hyaluronic gel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Office second look hysteroscopy
Description: Second-look hysteroscopy after three months
Study: NCT03174067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: The participant receives buprenorphine
Study: NCT02329041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath Series 5
Description: one kind of videolaryngoscopes, which are widely used in airway management.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: another kind of videolaryngoscopes, which are also widely used in airway management.
Study: NCT02950194

Intervention type: PROCEDURE
Intervention: PPAWI
Description: One-step procedure of a panniculectomy performed by a plastic surgeon together with a mesh augmentation of the abdominal wall by a general surgeon.
Study: NCT00219739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg
Study: NCT00030381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4'-iodo-4'-deoxydoxorubicin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00315055

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP~T vaccine
Description: 0.5 mL, Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV//PRP~T combined
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: 0.5 mL, IM
Study: NCT00909766

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 28 days
Study: NCT04395755

Intervention type: BEHAVIORAL
Intervention: Generalized Anxiety Disorder-7 (GAD-7)
Description: The GAD-7 is useful in primary care and mental health settings as a screening tool and symptom severity measure for the four most common anxiety disorders.

Intervention type: BEHAVIORAL
Intervention: Patient Health Questionnaire-9 (PHQ-9)
Description: The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.
Study: NCT00219739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 600 mg
Study: NCT00496379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZK219477
Description: Given intravenously over approximately 30 minutes once every 3 weeks
Study: NCT02287649

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Study: NCT01704846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA 120 mg capsule
Description: 1capsule of BI 201335 NA 120 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA 120 mg capsule
Description: 1 capsule of BI 201335 NA 120 mg capsule
Study: NCT00454064

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive-behavioral treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive-behavioral treatment
Study: NCT00219739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg + Peg-Interferon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg + Peg-Interferon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg + Peg-Interferon
Study: NCT03323229

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Enhanced communications & ultrasound
Description: Paramedics will perform standardised point-of-care ultrasound scan protocols (specific to the patient's symptom set) and record a short (\<1 minute) video summarising the patient's condition and current management. These will be transmitted via satellite to consultants at the receiving hospital before the ambulance leaves the incident scene. The emergency department consultants will provide support and advice on continuing patient management via standard ambulance communications systems while it is en route to the hospital.
Study: NCT01213433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-Amodiaquine
Description: Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008.It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
Study: NCT02600026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DriveCam
Description: Video event monitoring device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DriveCam
Description: Video event monitoring device

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Video feedback intervention
Study: NCT00696657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 0.1 mg, once weekly, s.c. injection
Study: NCT00219739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg + Peg-Interferon
Study: NCT00696657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 0.2 mg, once weekly, s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 0.4 mg, once weekly, s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 0.8 mg, once weekly, s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 0.8 mg with titration, once weekly, s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: 1.6 mg with titration, once weekly, s.c. injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.1 mg, once weekly, s.c. injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.2 mg, once weekly, s.c. injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.4 mg, once weekly, s.c. injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.8 mg with titration, once weekly, s.c. injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.8 mg with titration, once weekly, s.c. injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1.6 mg, once weekly, s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.2 mg with titration, once daily, s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg with titration, once daily, s.c. injection
Study: NCT03174067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: The participant receives clonidine
Study: NCT03639402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education classes
Description: Community empowerment through involvement of local mothers (peer mothers) for dissemination of education regarding health diet and physical activity to others eligible mothers in the community (fellow mothers).
Study: NCT01766687

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydration
Study: NCT00937105

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon A contact lenses
Description: FDA approved soft contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon A contact lenses
Description: FDA approved soft contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renu Multiplus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care
Study: NCT00219739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg + Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg + Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg + Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg + Cytarabine